Skip Navigation LinksHome > October 2012 - Volume 35 - Issue 8 > Safety and Immunogenicity of Vaccination With MART-1 (26-35,...
Text sizing:
A
A
A
Journal of Immunotherapy:
doi: 10.1097/CJI.0b013e318271fa57
Erratum

Safety and Immunogenicity of Vaccination With MART-1 (26-35, 27 L), gp100 (209-217, 210 M), and Tyrosinase (368-376, 370D) in Adjuvant With PF-3512676 and GM-CSF in Metastatic Melanoma: Erratum

Free Access

The article by Tarhini et al,1 appearing on page 359 of the May 2012 issue of the Journal of Immunotherapy, published with an incomplete Acknowledgments section. The complete paragraph appears below and the online version of the article has been corrected.

“The project described was supported by Award Number P50CA121973 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.”

Back to Top | Article Outline

REFERENCE

1. Tarhini AA, Leng S, Moschos SJ, et al. Safety and immunogenicity of vaccination with MART-1 (26-35, 27 l), gp100 (209-217, 210 M), and tyrosinase (368-376, 370D) in adjuvant with pf-3512676 and GM-CSF in metastatic melanoma. J Immunotherapy. 2012;35:359–366

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Call for Papers

Journal of Immunotherapy has issued a call for papers. With an impact factor of 3.203, JOI is a leading journal in the fields of immunology and oncology.

For manuscript submission, go to: http://www.editorialmanager.com/jit/

Connect With Us

Twitter
twitter.com/JOFIonline

For additional oncology content, visit LWW Oncology Journals on Facebook.